Imagine trying to pick out a few specific seeds from a giant pile of sand using only a tiny pair of tweezers. This technology uses light beams and AI to automatically find and move tiny clusters of patient cells into test tubes. It's like having a smart robot that organizes biological samples perfectly so scientists can test new medicines more accurately.
Pharmaceutical companies struggle to predict how drug candidates will affect specific patient subgroups before clinical trials. Current methods for isolating patient-derived 3D cell cultures are not selective or scalable enough for high-throughput screening.
An AI-assisted cell-handling platform combining microfluidics and optical tweezers. It includes a 3D-printed microfluidic module capable of sorting and dispensing spheroids into 384 well-plates.
If you are a drug discovery firm dealing with unpredictable drug toxicity in clinical trials — this project developed an AI-assisted cell handling platform that isolates patient-derived 3D cell cultures to better predict drug effects before human testing.
If you are a personalized medicine provider dealing with variations in drug efficacy across patient subgroups — this project developed a system to automatically detect spheroid viability and dispense them into 384 well-plates for high-throughput screening.
If you are a toxicology lab dealing with the slow manual process of isolating 3D cell cultures — this project developed a microfluidic sorting-dispensing tool that handles samples from 20 to 50 micrometers to speed up the screening workflow.
Based on available project data, specific pricing or cost-per-test details are not provided; however, the goal is to develop treatments at a lower cost.
Yes, the project focuses on high-throughput drug screening by automating the isolation and dispensing of spheroids into 384 well-plates.
Based on available project data, specific patent or licensing terms are not mentioned, but the technology is being developed by Lucero AB.
The system is designed to be a benchtop device that dispenses individual spheroids in 2 microlitre droplets into commercially available well-plates.
The project period runs from 2023-01-01 to 2026-03-31, aiming to reach TRL 6 and CRL 6 by the end of the term.
The project is led by a single Swedish SME, Lucero AB, which holds 100% of the industry ratio. This lean structure suggests a fast-paced, agile development cycle, though it relies heavily on a 'large European pharmaceutical partner' for on-site validation to reach TRL 6.
Contact Lucero AB in Sweden
Contact us to connect with Lucero AB for pilot integration.
